Madrigal Pharmaceuticals Stock Performance

MDGL Stock  USD 331.45  5.29  1.57%   
On a scale of 0 to 100, Madrigal Pharmaceuticals holds a performance score of 9. The company secures a Beta (Market Risk) of 0.34, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Madrigal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Madrigal Pharmaceuticals is expected to be smaller as well. Please check Madrigal Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Madrigal Pharmaceuticals' current price movements will revert.

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(1.57)
Five Day Return
2.39
Year To Date Return
46.1
Ten Year Return
198.74
All Time Return
4.18
Last Split Factor
1:35
Dividend Date
2016-07-25
Last Split Date
2016-07-25
1
Disposition of 6363 shares by William Sibold of Madrigal Pharmaceuticals at 243.83 subject to Rule 16b-3
09/09/2024
2
Disposition of 15000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3
09/13/2024
3
Disposition of 18917 shares by Taub Rebecca of Madrigal Pharmaceuticals at 245.3356 subject to Rule 16b-3
09/20/2024
4
Disposition of 000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3
10/04/2024
5
Viking Stock Rises 29 percent in Three Months Time to Buy, Hold or Sell
10/18/2024
6
Acquisition by Friedman Paul A of 26270 shares of Madrigal Pharmaceuticals at 9.45 subject to Rule 16b-3
10/22/2024
7
Madrigal Pharmaceuticals director Richard Levy sells 1.5m in shares
11/06/2024
8
Heres Why Madrigal is a Great Momentum Stock to Buy
11/07/2024
9
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
11/08/2024
10
Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therapies Inc
11/14/2024
11
Janus Henderson Group PLCs Strategic Reduction in Madrigal Pharmaceuticals Inc
11/15/2024
12
Madrigal shares rise as Oppenheimer lifts target to 400
11/20/2024
13
Connor Clark Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc.
11/21/2024
14
Madrigal Just Flashed Golden Cross Signal Do You Buy
11/22/2024
15
Disposition of 1200 shares by Craves Fred B of Madrigal Pharmaceuticals at 350.7146 subject to Rule 16b-3
11/25/2024
Begin Period Cash Flow331.5 M
  

Madrigal Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  24,713  in Madrigal Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of  8,432  from holding Madrigal Pharmaceuticals or generate 34.12% return on investment over 90 days. Madrigal Pharmaceuticals is currently generating 0.5561% in daily expected returns and assumes 4.62% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Madrigal, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 5.99 times more return on investment than the market. However, the company is 5.99 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of risk.

Madrigal Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Madrigal Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Madrigal Pharmaceuticals, and traders can use it to determine the average amount a Madrigal Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1204

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsMDGL
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 4.62
  actual daily
41
59% of assets are more volatile

Expected Return

 0.56
  actual daily
11
89% of assets have higher returns

Risk-Adjusted Return

 0.12
  actual daily
9
91% of assets perform better
Based on monthly moving average Madrigal Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Madrigal Pharmaceuticals by adding it to a well-diversified portfolio.

Madrigal Pharmaceuticals Fundamentals Growth

Madrigal Stock prices reflect investors' perceptions of the future prospects and financial health of Madrigal Pharmaceuticals, and Madrigal Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Madrigal Stock performance.

About Madrigal Pharmaceuticals Performance

By examining Madrigal Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Madrigal Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Madrigal Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.58)(0.61)
Return On Capital Employed(0.73)(0.77)
Return On Assets(0.58)(0.61)
Return On Equity(0.92)(0.88)

Things to note about Madrigal Pharmaceuticals performance evaluation

Checking the ongoing alerts about Madrigal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Madrigal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Madrigal Pharmaceuticals appears to be risky and price may revert if volatility continues
Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 91.0% of the company shares are owned by institutional investors
Latest headline from fool.com: Disposition of 1200 shares by Craves Fred B of Madrigal Pharmaceuticals at 350.7146 subject to Rule 16b-3
Evaluating Madrigal Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Madrigal Pharmaceuticals' stock performance include:
  • Analyzing Madrigal Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Madrigal Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Madrigal Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Madrigal Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Madrigal Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Madrigal Pharmaceuticals' stock. These opinions can provide insight into Madrigal Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Madrigal Pharmaceuticals' stock performance is not an exact science, and many factors can impact Madrigal Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.02)
Revenue Per Share
3.705
Return On Assets
(0.52)
Return On Equity
(1.30)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.